The Centre for Drug Design and Discovery (CD3) translates innovative science into promising drug discovery programs that are well qualified for further development by pharmaceutical or biotech companies. CD3 brings expert drug discovery capabilities and financial means to academic research groups and small companies in order to discover innovative small molecule drugs. Supported by KU Leuven Research & Development and the European Investment Fund, CD3 launched a 60 million euro fund in 2016.
KU Leuven Research & Development (LRD) is dedicated to building bridges between science and industry. By transferring knowledge and technologies to society and the marketplace, LRD advances the impact of research results on people’s lives around the globe. Established in 1972, LRD has developed a solid tradition of collaborating with industry, securing and licensing intellectual property rights, creating spin-off companies and stimulating knowledge-driven regional development.